HC Wainwright reissued their buy rating on shares of Barinthus Biotherapeutics (NASDAQ:BRNS – Free Report) in a research report sent to investors on Friday, Benzinga reports. The brokerage currently has a $8.00 price target on the stock.
Separately, William Blair reissued an outperform rating on shares of Barinthus Biotherapeutics in a research report on Monday, January 8th.
Read Our Latest Stock Analysis on BRNS
Barinthus Biotherapeutics Price Performance
Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) last issued its quarterly earnings results on Wednesday, March 20th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.10. On average, equities research analysts anticipate that Barinthus Biotherapeutics will post -2.6 EPS for the current fiscal year.
Barinthus Biotherapeutics Company Profile
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
See Also
- Five stocks we like better than Barinthus Biotherapeutics
- Business Services Stocks Investing
- MarketBeat Week in Review – 4/15 – 4/19
- Investing in the High PE Growth Stocks
- Comprehensive Analysis of PayPal Stock
- Canada Bond Market Holiday: How to Invest and Trade
- Intuitive Surgical Stock Can Trend Much Higher This Year
Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.